|Day Low/High||553.00 / 571.41|
|52 Wk Low/High||433.52 / 672.34|
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
The Real Money Post Industrial Average is now up 18.2% -- here's why it could still plow ahead of the Dow and S&P 500.
What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?
The name is on Jim Cramer's buy-the-dip list, so let's check it out and see where traders could buy strength.
The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.
Shares of the maker of life sciences equipment appear ready to head higher after a period of consolidation.
Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.
Let's not kid ourselves that there is any longer some kind of relationship between price and value. Or fact and truth.
Top investment ideas from seven of CFRA Research's equity analysts.
The great news about the pent-up demand rally? While these stocks have been creeping up they are now going to explode higher.
The RMPIA also tops other indexes for year, shooting ahead 29%.
The average declined in October, but it was less than that hit took by the major indexes.
TMO has one of the most stable-looking uptrends around.
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
The charts of the life sciences company suggest its stock could make a large upside move.
The markets are really in the hands of Washington right now, and Washington is in the hands of the virus.
This list is not a buy list but a list of stocks that have been brought to new heights.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
After a strong day for fixed-income markets, let's learn from 2008 how to play this volatility.
The pace of the selloff in shares of the maker of lab equipment has begun to slow and that is a positive.
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
It's no secret that the Fed would like to get out of the short-term repo business.
The charts of TMO are positive.